Hanall Biopharma (009420) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hanall Biopharma (009420) has a cash flow conversion efficiency ratio of 0.047x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.34 Billion ≈ $4.98 Million USD) by net assets (₩157.65 Billion ≈ $106.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 009420 stock market capitalisation for the company's overall valuation and market capitalisation.
Hanall Biopharma - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Hanall Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hanall Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hanall Biopharma ranked by their cash flow conversion efficiency. Explore Hanall Biopharma (009420) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TSE Co. Ltd
KQ:131290
|
0.088x |
|
Luxin Venture Capital Group Co Ltd
SHG:600783
|
0.009x |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
0.145x |
|
Capri Holdings Ltd
NYSE:CPRI
|
1.874x |
|
Ningbo Shuanglin Auto Parts
SHE:300100
|
0.079x |
|
Nexa Resources SA
NYSE:NEXA
|
0.074x |
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SHG:600063
|
0.005x |
|
OC Oerlikon Corp AG
SW:OERL
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Hanall Biopharma (2011–2024)
The table below shows the annual cash flow conversion efficiency of Hanall Biopharma from 2011 to 2024. View current stock price of Hanall Biopharma for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩168.35 Billion ≈ $114.09 Million |
₩9.36 Billion ≈ $6.34 Million |
0.056x | -65.07% |
| 2023-12-31 | ₩186.22 Billion ≈ $126.20 Million |
₩29.64 Billion ≈ $20.09 Million |
0.159x | +6.27% |
| 2022-12-31 | ₩168.26 Billion ≈ $114.03 Million |
₩25.20 Billion ≈ $17.08 Million |
0.150x | +2816.00% |
| 2021-12-31 | ₩163.49 Billion ≈ $110.80 Million |
₩839.87 Million ≈ $569.17K |
0.005x | +0.21% |
| 2020-12-31 | ₩181.27 Billion ≈ $122.85 Million |
₩929.29 Million ≈ $629.77K |
0.005x | -96.49% |
| 2019-12-31 | ₩140.42 Billion ≈ $95.16 Million |
₩20.49 Billion ≈ $13.89 Million |
0.146x | +669.79% |
| 2018-12-31 | ₩116.92 Billion ≈ $79.23 Million |
₩-2.99 Billion ≈ $-2.03 Million |
-0.026x | -106.76% |
| 2017-12-31 | ₩111.20 Billion ≈ $75.36 Million |
₩42.14 Billion ≈ $28.56 Million |
0.379x | +901.08% |
| 2016-12-31 | ₩104.36 Billion ≈ $70.72 Million |
₩3.95 Billion ≈ $2.68 Million |
0.038x | +893.87% |
| 2015-12-31 | ₩95.22 Billion ≈ $64.53 Million |
₩-454.02 Million ≈ $-307.69K |
-0.005x | +93.79% |
| 2014-12-31 | ₩45.81 Billion ≈ $31.04 Million |
₩-3.52 Billion ≈ $-2.38 Million |
-0.077x | +41.14% |
| 2013-12-31 | ₩59.63 Billion ≈ $40.41 Million |
₩-7.78 Billion ≈ $-5.27 Million |
-0.130x | -567.19% |
| 2012-12-31 | ₩78.67 Billion ≈ $53.31 Million |
₩2.20 Billion ≈ $1.49 Million |
0.028x | -80.90% |
| 2011-12-31 | ₩50.70 Billion ≈ $34.36 Million |
₩7.41 Billion ≈ $5.02 Million |
0.146x | -- |
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more